H.C. Wainwright raises US Antimony stock price target on inventory build

US Antimony reported Q1 fiscal 2026 revenue of $6.8 million, well below the $19.7 million consensus, and an EPS loss of $0.08 versus expectations for a near-breakeven result. The company also posted a net loss of $11.3 million versus $0.5 million of net income a year ago, while recognizing no revenue from its $245.0 million Defense Logistics Agency contract. H.C. Wainwright still raised its price target slightly to $11.75 from $11.50 and kept a Buy rating, but the quarter was described as transitional with capital being deployed into inventory and capacity buildout.

Analysis

The market is still treating this as a simple earnings miss, but the more important signal is that the company is front-loading capital ahead of an eventual government-linked ramp while monetization remains delayed. That creates a classic setup where reported earnings can look terrible for multiple quarters even as operating leverage improves later, which means the stock may stay headline-sensitive until there is proof of conversion from inventory and receivables into cash. The near-term winner in this setup is not necessarily the issuer itself, but any upstream suppliers of ore, processing equipment, logistics, or labor that can capture the buildout spend without the same execution risk.

The key risk is balance-sheet timing mismatch: inventory build plus large receivables can compress liquidity right when investors are demanding evidence of contract execution. If the ramp slips another quarter, the market will likely re-rate the name on working-capital stress rather than growth optionality, and that can happen quickly over days to weeks. Conversely, a single quarter of meaningful contract recognition would likely produce a violent squeeze because expectations are already depressed and positioning is likely crowded on the wrong side.

This is less a fundamental short into oblivion than a timing trade. The bull case hinges on whether the company can turn the contract into revenue within the next 1-2 quarters; absent that, the equity can underperform despite the strategic narrative. The contrarian point is that the market may be over-discounting the transition phase and underestimating how quickly a defense-supply name can rerate once revenue visibility appears, but until then the burden of proof sits squarely with management.

For cross-asset context, this is a niche beneficiary of the broader defense/critical-minerals theme, but the benefit is idiosyncratic rather than sector-wide. If the contract ramp becomes visible, peers with less working-capital strain and cleaner execution should be preferred as the better-quality expression of the same thematic exposure.

Key Decisions for Investors

• Short UAMY into any post-earnings relief rally over the next 1-3 weeks; thesis is that working-capital strain will dominate until contract revenue is recognized. Risk: a surprise contract fill could trigger a sharp squeeze.
• If you want bullish exposure, use call spreads instead of equity in UAMY over a 2-4 month horizon; the upside is convex if revenue starts to convert, but the premium protects against another delayed-quarter drawdown.
• Pair trade: long a higher-quality defense/critical-minerals beneficiary vs. short UAMY for 1-2 quarters. This isolates the theme while fading execution risk and balance-sheet noise.
• Set a catalyst trigger on the next quarterly report: if contract revenue remains immaterial while inventory keeps rising, add to the short; if revenue begins to inflect, cover immediately because the stock can reprice faster than fundamentals.